HIV Pricing Programs Can Help, But More Access And Innovation Needed - IFPMA
This article was originally published in PharmAsia News
Executive Summary
HONG KONG - Innovative and generic companies both contribute to the fight against HIV/AIDS, and while putting downward pressure on prices to improve access remains important, new novel medicines are still needed, suggests a new report on access to HIV/AIDS medicines